The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Since the launch in 2019, 80 partners representing key stakeholders in the field have worked together to build an ecosystem that can empower pregnant and breastfeeding women to make informed decisions about medicines. On June 13-14, The IMI ConcePTION consortium convened one last time at the historic De Bazel building in Amsterdam to reflect on the advancements and make plans for the last six months of the project.
Over the course of two days, the participants discussed what needs to happen before the end of the year, and how our efforts can be sustained. The outcome of the ConcePTION project is a set of systems that can generate evidence on medicine safety in pregnancy and breastfeeding. Since the beginning in 2019, we have developed data-driven approaches to study medicines in, along with a longitudinal system to study exposure to medicines in utero. This “Lifetime” framework system is already used in four European pilot centres, and has recruited 1,200 mother-child pairs. We have also developed in vitro, in vivo and in silico tools to study how maternal medicines transfer to the infant via breastfeeding, and infrastructures for clinical lactation studies.
Disseminating information about medicine safety in pregnancy and breastfeeding is another important objective for the ConcePTION project. During the meeting, we launched the MUMS knowledge bank, designed to provide guidance and advice for women and healthcare professionals. Another important result of the project is a set of e-learning modules for health care professionals.
All of this and more will be made available on the ConcePTION website before the project comes to an end in December 2024.
Participants at the ConcePTION General Assembly Meeting in Amsterdam 13-14 June 2024